Novo Nordisk announced strong performance metrics for its weight-loss medication Wegovy, with total prescriptions reaching approximately 1.3 million in the first quarter and exceeding 2 million since the drug's launch.

The Danish pharmaceutical company has raised its financial guidance based on the successful rollout of the obesity treatment. Company officials indicated that the drug's performance will help offset declining sales in other segments of their business.

Wegovy, which is part of a class of medications known as GLP-1 receptor agonists, has gained significant market traction since its introduction. The medication works by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite and weight loss.

Recent clinical research has also suggested potential cardiovascular benefits associated with the medication. Studies indicate the drug may reduce heart attack risk by approximately 13 percent, though this represents preliminary findings that require further validation.

The strong adoption of Wegovy reflects growing demand for pharmaceutical interventions in obesity treatment. The medication's commercial success has positioned Novo Nordisk favorably in the competitive weight management market, contributing to the company's revised financial outlook for the current reporting period.